Mustafa Gokhan ERTOSUN, Sayra DİLMAC, Fatma Zehra HAPİL, Gamze TANRİOVER, Sadi KOKSOY, Osman Nidai OZES

Regulation of E2F1 activity via PKA-mediated phosphorylations

E2F1 becomes activated during the G1 phase of the cell cycle, and posttranslational modifications modulate its activity. Activation of G-protein coupled receptors (GPCR) by many ligands induces the activation of adenylate cyclases and the production of cAMP, which activates the PKA enzyme. Activated PKA elicits its biological effect by phosphorylating the target proteins containing serine or threonine amino acids in the RxxS/T motif. Since PKA activation negatively regulates cell proliferation, we thought that activated PKA would negatively affect the activity of E2F1. In line with this, when we analyzed the amino acid sequence of E2F1, we found 3 hypothetical consensus PKA phosphorylation sites located at 127-130, 232-235, and 361-364 positions and RYET, RLLS, and RMGS sequences. After showing the binding and phosphorylation of E2F1 by PKA, we converted the codons of Threonine-130, Serine-235, and Serine-364 to Alanine and Glutamic acid codons on the eukaryotic E2F1 expression vector we had previously created. We confirmed the phosphorylation of T130, S235, and S364 by developing monoclonal antibodies against phospho-specific forms of these sites and showed that their phosphorylation is cell cycle-dependent. According to our results, PKA-mediated phosphorylation of E2F1 by PKA inhibits proliferation and glucose uptake and induces caspase-3 activation and senescence.

Keywords:

E2F1, cell cycle, PKA, forskolin, senescence, proliferation,

PDF

___

Anghileri P, 1999, EXP CELL RES, V250, P510, DOI 10.1006/excr.1999.4531
Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428
BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352
BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0
Berger B, 2010, NEURO-ONCOLOGY, V12, P894, DOI 10.1093/neuonc/noq051
Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309
Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536
Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994
Costanzo V, 1999, CURR BIOL, V9, P903, DOI 10.1016/S0960-9822(99)80395-9
Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104
DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215
Ertosun MG, 2016, CYTOKINE GROWTH F R, V31, P17, DOI 10.1016/j.cytogfr.2016.02.001
Ferretti AC, 2016, ONCOTARGET, V7, P17815, DOI 10.18632/oncotarget.7404
Garcia-Alvarez G, 2007, BBA-MOL CELL RES, V1773, P375, DOI 10.1016/j.bbamcr.2006.09.015
Hazar-Rethinam M, 2011, INT J MOL SCI, V12, P8947, DOI 10.3390/ijms12128947
HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501
Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200
Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006
Inoshita S, 1999, KIDNEY INT, V56, P2085, DOI 10.1046/j.1523-1755.1999.00799.x
Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614
Ivanova IA, 2009, ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354
Jensen J, 2007, BRIT J PHARMACOL, V151, P423, DOI 10.1038/sj.bjp.0707248
Jewell JL, 2019, ELIFE, V8, DOI 10.7554/eLife.43038
Johnson JL, 2012, CANCER RES, V72, P516, DOI 10.1158/0008-5472.CAN-11-2647
KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O
Kaihara KA, 2015, DIABETES, V64, P1688, DOI 10.2337/db14-1051
Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7
Kumari A, 2015, CELL DEATH DIFFER, V22, P311, DOI 10.1038/cdd.2014.146
Lin WC, 2001, GENE DEV, V15, P1833 .
Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659
Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761
Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887
Medina EA, 2014, LEUKEMIA, V28, P2080, DOI 10.1038/leu.2014.112
Mohan V, 2012, EXP NEUROL, V237, P477, DOI 10.1016/j.expneurol.2012.07.019
Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201
Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146
Olmos Y, 2011, DRUG RESIST UPDATE, V14, P35, DOI 10.1016/j.drup.2010.12.001
Ozes AR, 2018, ONCOGENE, V37, P3589, DOI 10.1038/s41388-018-0218-z
Pediconi N, 2009, MOL CELL BIOL, V29, P1989, DOI 10.1128/MCB.00552-08
PEEPER DS, 1995, ONCOGENE, V10, P39 .
Pillai S, 2010, CANCER RES, V70, P4931, DOI 10.1158/0008-5472.CAN-10-0501
QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918
Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4
SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166
SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610
Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859
Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974
Takahashi Y, 2000, GENE DEV, V14, P804 .
Tantini B, 2005, BASIC RES CARDIOL, V100, P131, DOI 10.1007/s00395-004-0504-5
Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559
WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602
Zhao J, 2013, ONCOGENE, V32, P3520, DOI 10.1038/onc.2012.364